Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Italy Fines Apple €98.6 Million Over App Store Dominance 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
GAITHERSBURG, Md., March 17, 2016 -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Bob Darius, Senior Vice President, Quality Operations. He will be responsible for leading the global Quality Operations of the company, including both Quality Assurance and Quality Control, as well as serving as a member of the company’s senior management team.
Mr. Darius joins Novavax with over 25 years of experience in Quality Assurance, Quality Control and strategic manufacturing. As VP Quality Operations at GlaxoSmithKline (GSK) Biologicals, he provided oversight of the North American and German Vaccine Manufacturing Operations for over 10 years and most recently transitioned to Head Quality Advocacy Liaison. Mr. Darius also held positions of increasing responsibility at the Food and Drug Administration, Center for Biologics Evaluation and Research, where he was a Senior Reviewer and Inspector, Advisor to the Deputy Center Director, Medicine, on counter-bioterrorism products. He earned a Bachelor of Science degree in Biology from George Mason University and completed graduate work in biotechnology at Johns Hopkins University.
“I am delighted to welcome Bob to the Novavax team,” said Stanley C. Erck, President and CEO. “At this critical stage of our development, during which we are implementing our commercialization plans for our RSV F Vaccine, Bob’s depth of experience and understanding of evolving regulatory and quality requirements will be critical to our success.”
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations [email protected] 240-268-2000
